UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of
1934
(Amendment No. 3)*
| SpringWorks Therapeutics, Inc. |
|
(Name of Issuer)
|
| COMMON STOCK |
|
(Title of Class of Securities)
|
| 85205L107 |
|
(CUSIP Number)
|
|
OrbiMed Advisors LLC
OrbiMed Capital GP VI LLC
601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400
|
|
(Name, Address and Telephone Number of Person Authorized
to
|
| September 12, 2022 |
| (Date of Event which Requires Filing of this Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7(b) for other parties to whom copies are to be sent.
| * | The remainder of this cover page shall be filled out for a Reporting Person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 85205L107 |
| 1 |
Names of Reporting Persons. OrbiMed Advisors LLC | |||
| 2 |
Check the Appropriate Box if a Member of a Group (See Instructions). (a) o (b) o |
| ||
| 3 |
SEC Use Only
| |||
| 4 |
Source of Funds (See Instructions) AF | |||
| 5 |
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
|
o | ||
| 6 |
Citizenship or Place of Organization Delaware | |||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
Sole Voting Power 0 | ||
| 8 |
Shared Voting Power 5,599,842 | |||
| 9 |
Sole Dispositive Power 0 | |||
| 10 |
Shared Dispositive Power 5,599,842 | |||
| 11 |
Aggregate Amount Beneficially Owned by Each Reporting Person 5,599,842 | |||
| 12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
|
o | ||
| 13 |
Percent of Class Represented by Amount in Row (11) 9.3%* | |||
| 14 |
Type of Reporting Person (See Instructions) IA | |||
* This percentage is calculated based upon 60,144,001 shares of common stock (“Shares”) outstanding of SpringWorks Therapeutics, Inc. (the “Issuer”), which includes (i) 49,442,662 Shares as set forth in the Issuer’s Quarterly Report for the quarter ending June 30, 2022 on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on August 4, 2022, (ii) 2,050,819 Shares issued and sold to Glaxo Group Limited in a private placement that closed on September 9, 2022 as set forth in the Issuer’s Current Report on Form 8-K filed with the SEC on September 7, 2022, and (iii) 8,650,520 Shares sold and issued by the Issuer to certain accredited investors in a private placement that closed on September 9, 2022 as set forth in the Issuer’s Current Report on Form 8-K filed with the SEC on September 8, 2022.
| CUSIP No. 85205L107 |
| 1 |
Names of Reporting Persons. OrbiMed Capital GP VI LLC | |||
| 2 |
Check the Appropriate Box if a Member of a Group (See Instructions). (a) o (b) o |
| ||
| 3 | SEC Use Only | |||
| 4 |
Source of Funds (See Instructions) AF | |||
| 5 | Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) | o | ||
| 6 |
Citizenship or Place of Organization Delaware | |||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
7 |
Sole Voting Power 0 | ||
| 8 |
Shared Voting Power 5,599,842 | |||
| 9 |
Sole Dispositive Power 0 | |||
| 10 |
Shared Dispositive Power 5,599,842 | |||
| 11 |
Aggregate Amount Beneficially Owned by Each Reporting Person 5,599,842 | |||
| 12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) | o | ||
| 13 |
Percent of Class Represented by Amount in Row (11) 9.3%* | |||
| 14 |
Type of Reporting Person (See Instructions) OO | |||
* This percentage is calculated based upon 60,144,001 shares of common stock (“Shares”) outstanding of SpringWorks Therapeutics, Inc. (the “Issuer”), which includes (i) 49,442,662 Shares as set forth in the Issuer’s Quarterly Report for the quarter ending June 30, 2022 on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on August 4, 2022, (ii) 2,050,819 Shares issued and sold to Glaxo Group Limited in a private placement that closed on September 9, 2022 as set forth in the Issuer’s Current Report on Form 8-K filed with the SEC on September 7, 2022, and (iii) 8,650,520 Shares sold and issued by the Issuer to certain accredited investors in a private placement that closed on September 9, 2022 as set forth in the Issuer’s Current Report on Form 8-K filed with the SEC on September 8, 2022.
Item 1. Security and Issuer
This Amendment No. 3 (“Amendment No. 3”) to Schedule 13D supplements and amends the statement on Schedule 13D (the “Statement”) filed by OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC originally filed with the Securities and Exchange Commission (the “SEC”) on September 25, 2019, as amended by Amendment No. 1 filed with the SEC on October 14, 2020 and Amendment No. 2 filed with the SEC on March 4, 2021. The Statement relates to the common stock, par value $0.0001 per share (the “Shares”) of SpringWorks Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Issuer”), with its principal executive offices located at 100 Washington Blvd., Stamford, CT 06902. The Shares are listed on the NASDAQ Global Select Market under the ticker symbol “SWTX”. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
This Amendment No. 3 is being filed to report that the beneficial ownership of the outstanding Shares held by the Reporting Persons (as defined below) was reduced by more than 1% since the last filing following the transaction described in Item 5(c) below.
Item 2. Identity and Background
(a) This Schedule 13D is being filed by OrbiMed Advisors LLC (“OrbiMed Advisors”) and OrbiMed Capital GP VI LLC (“OrbiMed GP”) (collectively, the “Reporting Persons”).
(b) — (c), (f) OrbiMed Advisors, a limited liability company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member or general partner of certain entities as more particularly described in Item 6 below. OrbiMed Advisors has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
OrbiMed GP, a limited liability company organized under the laws of Delaware, is the general partner of a limited partnership as more particularly described in Item 6 below. OrbiMed GP has its principal offices at 601 Lexington Avenue, 54th Floor, New York, New York 10022.
The directors and executive officers of OrbiMed Advisors and OrbiMed GP are set forth on Schedules I and II, respectively, attached hereto. Schedules I and II set forth the following information with respect to each such person:
(i) name;
(ii) business address;
(iii) present principal occupation of employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and
(iv) citizenship.
(d) — (e) During the last five years, neither the Reporting Persons nor any Person named in Schedules I and II has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
Not applicable.
Item 4. Purpose of Transaction
The Shares were initially acquired by the Reporting Persons for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer’s business on behalf of the Reporting Persons’ respective advisory clients.
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions.
Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Issuer’s capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer’s business or corporate structure, (g) any change in the Issuer’s charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer’s securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above.
Item 5. Interest in Securities of the Issuer
(a) — (b) The following disclosure is based upon 60,144,001 outstanding Shares, including (i) 49,442,662 Shares outstanding as set forth in the Issuer’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2022, filed with the SEC on August 4, 2022, (ii) 2,050,819 Shares issued and sold to Glaxo Group Limited in a private placement that closed on September 9, 2022 as set forth in the Issuer’s Current Report on Form 8-K filed with the SEC on September 7, 2022, and (iii) 8,650,520 Shares sold and issued by the Issuer to certain accredited investors in a private placement that closed on September 9, 2022 as set forth in the Issuer’s Current Report on Form 8-K filed with the SEC on September 8, 2022.
As of the date of this filing, OrbiMed Private Investments VI, LP (“OPI VI”), a limited partnership organized under the laws of Delaware, holds 5,599,842 Shares constituting approximately 9.3% of the issued and outstanding Shares. OrbiMed GP is the general partner of OPI VI, pursuant to the terms of the limited partnership agreement of OPI VI, and OrbiMed Advisors is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. As a result, OrbiMed Advisors and OrbiMed GP share power to direct the vote and disposition of the Shares held by OPI VI and may be deemed directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI.
In addition, OrbiMed Advisors and OrbiMed GP, pursuant to their authority under the limited partnership agreements of OPI VI, caused OPI VI to enter into the agreements referred to in Item 6 below.
(c)
| Seller | Date of Transaction | Transaction | Number of Shares | Price Per Share |
| OPI VI | August 8, 2022 | Sold | 205,000 | $38.33 |
| OPI VI | August 9, 2022 | Sold | 69,568 | $37.47 |
| OPI VI | September 12, 2022 | Sold | 123,897 | $31.96 |
| OPI VI | September 12, 2022 | Sold | 30,000 | $31.98 |
Except as disclosed above, none of the Reporting Persons has effected any transaction during the past sixty (60) days in any Shares.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed GP is the general partner of OPI VI, pursuant to the terms of the limited partnership agreement of OPI VI. Pursuant to this agreement and relationship, OrbiMed GP has discretionary investment management authority with respect to the assets of OPI VI. Such authority includes the power to vote and otherwise dispose of securities held by OPI VI. The number of outstanding Shares attributable to OPI VI is 5,599,842. OrbiMed GP, pursuant to its authority under the limited partnership agreement of OPI VI, may be considered to hold indirectly 5,599,842 Shares.
OrbiMed Advisors is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. Pursuant to these agreements and relationships, OrbiMed Advisors and OrbiMed GP have discretionary investment management authority with respect to the assets of OPI VI. Such authority includes the power of OrbiMed GP to vote and otherwise dispose of securities held by OPI VI. The number of outstanding Shares attributable to OPI VI is 5,599,842 Shares. OrbiMed Advisors, pursuant to its authority under the terms of the limited liability company agreement of OrbiMed GP, may also be considered to hold indirectly 5,599,842 Shares.
Investors’ Rights Agreement
In addition, OPI VI and certain other stockholders of the Issuer entered into an amended and restated investors’ rights agreement with the Issuer, dated as of August 30, 2019, as amended February 25, 2021 (the “Investors’ Rights Agreement”). Pursuant to the Investors’ Rights Agreement and subject to the terms and conditions therein, the parties agreed that:
Registration Rights
Following the closing of the Issuer’s initial public offering (the “IPO”), the holders of a certain number of Shares, or their transferees, will be entitled to the registration rights set forth below with respect to registration of the resale of such shares under the Securities Act of 1933, as amended (the “Securities Act”) pursuant to the Investors’ Rights Agreement.
Demand Registration Rights
At any time beginning six months following the date of the underwriting agreement of the IPO, the holders of at least 20% of the registrable securities then outstanding of the Issuer may make a written request that the Issuer register some or all of their registrable securities, subject to certain specified conditions and exceptions. If the anticipated aggregate offering price, net of selling expenses, would exceed five million dollars ($5,000,000), then the Issuer is required to use commercially reasonable efforts to effect the registration and will pay all registration expenses, other than underwriting discounts and commissions, related to any demand registration. The Issuer is not obligated to effect more than two of these registrations.
Piggyback Registration Rights
Whenever the Issuer proposes to file a registration statement under the Securities Act, OPI VI will be entitled to notice of the registration and have the right to include its shares in the registration.
Form S-3 Registration Rights
Pursuant to the Investors’ Rights Agreement, at any time after the Issuer is qualified to file a registration statement on Form S-3 under the Securities Act, and subject to limitations and conditions specified in the Investors’ Rights Agreement, the holders of at least 20% of the registrable securities then outstanding of the Issuer may make a written request that the Issuer prepare and file a registration statement on Form S-3 covering their shares, so long as the aggregate price to the public equals or exceeds $2,000,000. The Issuer is not obligated to effect more than two of these Form S-3 registrations in any 12-month period.
Item 7. Material to Be Filed as Exhibits
| Exhibit | Description |
| 1. | Joint Filing Agreement among OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC. |
| 2. | Amended and Restated Investors’ Rights Agreement by and among the Issuer and certain of its stockholders, dated as of August 30, 2019 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1/A filed with the SEC on September 12, 2019). |
| 3. | Amendment to the Amended and Restated Investors’ Rights Agreement, dated as of February 25, 2021 (Incorporated by Reference to Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 25, 2021). |
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Dated: September 14, 2022 | ORBIMED ADVISORS LLC | ||
| By: | /s/ Carl L. Gordon | ||
| Name: Carl L. Gordon | |||
| Title: Member | |||
| ORBIMED CAPITAL GP VI LLC | |||
| By: | ORBIMED ADVISORS LLC, its managing member | ||
| By: | /s/ Carl L. Gordon | ||
| Name: Carl L. Gordon | |||
|
Title: Member of OrbiMed Advisors LLC
|
|||
SCHEDULE I
The names and present principal occupations of each of the executive officers and directors of OrbiMed Advisors LLC are set forth below. Unless otherwise noted, each of these persons is a United States citizen and has a business address of 601 Lexington Avenue, 54th Floor, New York, NY 10022.
| Name | Position with Reporting Person | Principal Occupation |
| Carl L. Gordon | Member |
Member OrbiMed Advisors LLC |
|
Sven H. Borho German and Swedish Citizen |
Member |
Member OrbiMed Advisors LLC |
| W. Carter Neild | Member |
Member OrbiMed Advisors LLC |
| Geoffrey C. Hsu | Member |
Member OrbiMed Advisors LLC |
| C. Scotland Stevens | Member |
Member OrbiMed Advisors LLC |
| David P. Bonita | Member |
Member OrbiMed Advisors LLC |
| Peter A. Thompson | Member |
Member OrbiMed Advisors LLC |
| Matthew S. Rizzo | Member |
Member OrbiMed Advisors LLC |
| Trey Block |
Chief Financial Officer
|
Chief Financial Officer OrbiMed Advisors LLC |
SCHEDULE II
The business and operations of OrbiMed Capital GP VI LLC are managed by the executive officers and directors of its managing member, OrbiMed Advisors LLC, set forth in Schedule I attached hereto.
EXHIBIT INDEX
| Exhibit | Description |
| 1. | Joint Filing Agreement among OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC. |
| 2. | Amended and Restated Investors’ Rights Agreement by and among the Issuer and certain of its stockholders, dated as of August 30, 2019 (incorporated by reference to Exhibit 4.2 to the Issuer’s Registration Statement on Form S-1/A filed with the SEC on September 12, 2019). |
| 3. | Amendment to the Amended and Restated Investors’ Rights Agreement, dated as of February 25, 2021 (Incorporated by Reference to Exhibit 4.4 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 25, 2021). |
Exhibit 1
JOINT FILING AGREEMENT
The undersigned hereby agree that the Statement on Schedule 13D, dated September 12, 2022 with respect to the ordinary shares of SpringWorks Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 14th day of September 2022.
| ORBIMED ADVISORS LLC | |||
| By: | /s/ Carl L. Gordon | ||
| Name: Carl L. Gordon | |||
| Title: Member | |||
| ORBIMED CAPITAL GP VI LLC | |||
| By: | ORBIMED ADVISORS LLC, its managing member | ||
| By: | /s/ Carl L. Gordon | ||
| Carl L. Gordon | |||
|
Title: Member of OrbiMed Advisors LLC
|
|||